The products proved to be failures in bioequivalence studies and contained active substance not conforming to specifications
Dubai: The Ministry of Health and Prevention issued on Wednesday four circulars withdrawing four batches of pharmaceutical products. Amoclan Suspension, used as an antibiotic; tablets F.C T mg40 10 20; and LIPOMAX, which is used to treat high cholesterol levels.
The circulars also included the withdrawal of all batches of the pharmaceutical product “Amniotic 5, 10 & 20 mg Tablets” used to treat blood pressure as well as three batches of “Daroxime 500mg Tablets” used as antibiotics.
The move comes after the ministry was alerted about these products for their failure in Bioequivalence studies and for containing an active substance not conforming to specifications.